4.7 Article

MiR-4763-3p targeting RASD2 as a Potential Biomarker and Therapeutic Target for Schizophrenia

Journal

AGING AND DISEASE
Volume 13, Issue 4, Pages 1278-1292

Publisher

INT SOC AGING & DISEASE
DOI: 10.14336/AD.2022.0103

Keywords

Schizophrenia; RASD2; miR-4763-3p; Biomarker

Funding

  1. National Key Research and Development Program of China [2020YFA0113000, 2018YFA0109800]
  2. Basic Research Program of Shanghai [20JC1412200]
  3. National Natural Science Foundation of China [81971324]
  4. Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (LCNBI)

Ask authors/readers for more resources

This study used a bioinformatics approach to identify differentially expressed genes in schizophrenia patients and found that miR-4763-3p regulates the downregulation of RASD2. The study also identified potential key brain regions in schizophrenia patients and discovered that inhibition of miR-4763-3p can alleviate symptoms. These findings suggest that miR-4763-3p may serve as a potential biomarker and therapeutic target for schizophrenia.
Existing diagnostic methods are limited to observing appearance and demeanor, even though genetic factors play important roles in the pathology of schizophrenia. Indeed, no molecular-level test exists to assist diagnosis, which has limited treatment strategies. To address this serious shortcoming, we used a bioinformatics approach to identify 61 genes that are differentially expressed in schizophrenia patients compared with healthy controls. In particular, competing endogenous RNA network revealed the important role of the gene RASD2, which is regulated by miR-4763-3p. Indeed, analysis of blood samples confirmed that RASD2 is downregulated in schizophrenia patients. Moreover, positron emission tomography data collected for 44 human samples identified the prefrontal and temporal lobes as potential key brain regions in schizophrenia patients. Mechanistic studies indicated that miR-4763-3p inhibits RASD2 by base-pairing with the 3' untranslated region of RASD2 mRNA. Importantly, RASD2 has been shown to interact with beta-arrestin2, which contributes to the regulation of the DRD2-dependent CREB response element-binding protein pathway in the dopamine system. Finally, results obtained with a mouse model of schizophrenia revealed that inhibition of miR-4763-3p function alleviated anxiety symptoms and improved memory. The dopamine transporters in the striatal regions were significantly reduced in schizophrenia model mice as compared with wild-type mice, suggesting that inhibition of miR-4763-3p can lessen the symptoms of schizophrenia. Our findings demonstrate that miR-4763-3p may target RASD2 mRNA and thus may serve as a potential biomarker and therapeutic target for schizophrenia, providing a theoretical foundation for further studies of the molecular basis of this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available